- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04712500
A Food-Effect Study of AND017 in Healthy Participants
May 7, 2021 updated by: Kind Pharmaceuticals LLC
A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period Crossover Study in Healthy Non-Elderly Chinese Subjects to Evaluate the Food Effect on the Pharmacokinetics of AND017 Following Oral Single-Dose Administration
The purpose of this phase I study is to evaluate the food effect on the PKs of AND017 following oral single-dose administration in healthy non-elderly Chinese subjects.
Study Overview
Detailed Description
This is a single-center, randomized, open-label, two-sequence, two-period crossover study in healthy non-elderly Chinese subjects to evaluate the food effect on the pharmacokinetics, as well as PD and safety of AND017 following oral single-dose administration
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- The First Affiliated Hospital of Soochow University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI between 19.0~26.0 kg/m2 (both inclusive); Body weight ≥50 kg for male, and ≥45 kg for female.
- Healthy participants having no clinical significant abnormalities of examinations during screening period and at the time of informed consent
- Have no pregnancy plan in the next six months and are willing to take effective contraceptive methods.
Exclusion Criteria:
- Allergic constitution or has a history of allergy to AND017 capsule and its excipient;
- Subjects with low blood pressure or a risk of low blood pressure: systolic pressure <90 mmHg, diastolic pressure<60 mmHg.
- Subjects with difficulty in venous blood sampling;
- Subjects with a history of drug abuse within the past five years or who have abused drug within the past three months before screening;
- Subjects smoking more than five cigarettes a day or nicotine dependent within the past three months before screening;
- Subjects drinking alcohol more than 14 U/week within the past six months or used any alcohol products in two days pre-dose;
- Subjects that have received any medication within the past 4 weeks pre-dose;
- Subjects that have taken food or drink that has the potential to induce or inhibit drug metabolizing enzymes in the liver within one-week pre-dose;
- Subjects that have taken any food or drink that contains or can be metabolized to caffeine or xanthine from 48 hours pre-dose to the last PK or PD blood sampling;
- Subjects with diseases or factors of clinical abnormalities that need to be excluded, including but not limited to the nervous system, cardiovascular system, kidney, liver, gastrointestinal, respiratory system, metabolism, and skeletal system diseases, or other factors that may affect drug absorption, distribution, metabolism and excretion;
- Subjects that have used HIF-PHIs within the past one year;
- Subjects positive in HIV-Ab, HBsAg or HBeAg, or HCV-Ab, TP-Ab;
- Subjects that have participated in any other clinical trials within the past three months pre-dose in the study;
- Female subjects of childbearing age who are pregnant, lactating, or planning pregnancy; or have a positive in pregnancy test during the study;
- Subjects with a history of blood donation or had a blood loss more than 400 mL within three months before screening;
- Subjects that have special requirements on diet and cannot follow the dietary program indicated in the study;
- Subjects that are unable to comply with research requirements or with any factors are considered not suitable for participating in the study according to the opinion of the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AND017: Fasted - Fed
Subjects were randomized to receive single dose of AND017 under fasted condition in Period 1 and under fed condition in Period 2
|
AND017 oral capsule
|
Experimental: AND017: Fed - Fasted
Subjects were randomized to receive single dose of AND017 under fed condition in Period 1 and under fasted condition in Period 2
|
AND017 oral capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Day 1 and Day 6, 0-72 hours post-dose
|
Maximum Observed Plasma Concentration for AND017
|
Day 1 and Day 6, 0-72 hours post-dose
|
AUC0-inf
Time Frame: Day 1 and Day 6, 0-72 hours post-dose
|
Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for AND017
|
Day 1 and Day 6, 0-72 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 30, 2020
Primary Completion (Actual)
August 16, 2020
Study Completion (Actual)
August 21, 2020
Study Registration Dates
First Submitted
January 13, 2021
First Submitted That Met QC Criteria
January 13, 2021
First Posted (Actual)
January 15, 2021
Study Record Updates
Last Update Posted (Actual)
May 11, 2021
Last Update Submitted That Met QC Criteria
May 7, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- AND017-CN-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on AND017
-
Kind Pharmaceuticals LLCNot yet recruiting
-
Kind Pharmaceuticals LLCNot yet recruitingMyelodysplastic Syndromes
-
Kind Pharmaceuticals LLCNot yet recruitingChemotherapy Induced Anemia
-
Kind Pharmaceuticals LLCCompleted
-
Kind Pharmaceuticals LLCNot yet recruitingCancer-Related Anemia
-
Kind Pharmaceuticals LLCCompletedRenal AnemiaChina, United States
-
Kind Pharmaceuticals LLCActive, not recruitingRenal AnemiaUnited States